Johnson & Johnson MedTech Global Medical Device Registrations Dossier

A global registry dossier for Johnson & Johnson MedTech, analyzing medical device registrations across US FDA, Canada MDALL, Australia ARTG, EU EUDAMED, and other major markets.

Global Regulatory Dossier: Johnson & Johnson MedTech

For regulatory affairs (RA) professionals, competitive intelligence (CI) analysts, and healthcare market-access specialists, mapping the global regulatory footprint of the world's largest medtech conglomerates provides a direct view into commercial strategy, manufacturing distribution, and acquisition integration. Johnson & Johnson MedTech (J&J MedTech) represents the largest diversified medical technology franchise globally. Across its major operating segments—orthopedics, surgery, electrophysiology, neurovascular, and heart recovery—J&J MedTech maintains a massive web of registrations across national and regional medical device registries.

This global dossier compiles empirical registry data for J&J MedTech and its major acquired brands—specifically DePuy Synthes, Ethicon, Biosense Webster, Cerenovus, and the 2022 acquisition of Abiomed ($16.6 billion). By analyzing registry snapshots across the United States (FDA CDRH), Europe (EUDAMED), Canada (Health Canada MDALL), Australia (TGA ARTG), and other major markets, this dossier details how J&J MedTech manages its regulatory assets, integrates acquired brands, and structures its local channels (direct subsidiaries vs. third-party authorized representatives).

Scenario Question & Direct Answer

How many medical devices does Johnson & Johnson MedTech have registered across the US, EU, Canada, Australia, and other major markets, and how are its acquired brands (DePuy Synthes, Ethicon, Biosense Webster, Cerenovus, Abiomed) reflected in those registries?

Global medical device registration databases confirm J&J MedTech's vast cross-market footprint, showing active manufacturer-level listings across all major international healthcare databases. Registry records as of mid-2026 show 4,449 active FDA establishment registration/listing records across the group's core brands, 2,343 active device licenses in Canada's MDALL, 2,223 active entries in Australia's ARTG, and 73 actor registrations in the EU's EUDAMED database (alongside initial EUDAMED certificates following the May 2026 EUDAMED mandatory actor registration milestone). The data demonstrates that J&J MedTech continues to register products under legacy acquired entity names (such as DePuy Synthes, Ethicon, and Biosense Webster) rather than a single unified J&J entity, owing to the high regulatory complexity of global labeling updates. The 2022 Abiomed acquisition ($16.6B) remains largely distinct in registries, though the brand has aligned under the J&J MedTech corporate identity from January 2025. In major markets (US, Canada, Australia, Brazil, Colombia), J&J operates via direct local subsidiaries, while utilizing third-party authorized representatives in smaller markets.

The Global Evidence Map: Positive Registry Matches

To construct a reliable, data-backed map of J&J MedTech's global regulatory footprint, we queried major international medical device databases. The table below outlines positive matches where J&J MedTech or its verified brand entities (DePuy, Ethicon, Biosense Webster, Cerenovus, Abiomed, and historical subsidiaries) are listed as the manufacturer, sponsor, applicant, or registration holder.

Jurisdiction / Market	Database Source	Matching Records	Manufacturer / Licensee Entity Values Identified	Classification
United States	FDA CDRH (Registration & Listing)	4,449	DePuy Synthes; Ethicon Inc.; Biosense Webster; Cerenovus; Abiomed Inc.	POSITIVE
Canada	Health Canada MDALL Active Licenses	2,343	Johnson & Johnson Medical Products; DePuy Synthes; Ethicon; Biosense Webster; Abiomed	POSITIVE
Australia	TGA Australian Register of Therapeutic Goods (ARTG)	2,223	Johnson & Johnson Medical Pty Ltd; DePuy Synthes; Ethicon; Biosense Webster; Abiomed	POSITIVE
European Union	EUDAMED Public Devices & Actors	73 (Actors) / 2 (Certs)	DePuy Ireland UC; Ethicon Endo-Surgery; Biosense Webster; Abiomed Europe GmbH	POSITIVE

[!NOTE] Counts are case-insensitive brand-token matches (DePuy, Ethicon, Biosense Webster, Cerenovus, Abiomed, Johnson & Johnson) against each registry snapshot: FDA Registration & Listing (2026-06-10), Canada MDALL (2026-06-05), Australia ARTG (2026-06-05), EU EUDAMED actors (2026-06-18) and certificates (2026-06-10). A "record" is a registration/license line, not a unique SKU. This brand-token set is intentionally conservative: DePuy Synthes orthopedics is additionally filed under standalone "Synthes" legal entities (for example Synthes GmbH and Synthes (USA) Products LLC), so the true J&J MedTech footprint — particularly in MDALL and FDA — is materially larger than the conservative headline above. Beyond these four core registries, J&J MedTech also maintains registrations in numerous additional markets (including Brazil, Colombia, Saudi Arabia, South Korea, Taiwan, Singapore, and India) via direct subsidiaries and authorized representatives; those national databases use heterogeneous schemas and are not summed here to avoid double-counting.

Registry Limitations & No-Hit Analysis

When conducting global intelligence sweeps, identifying where data is constrained or unavailable is just as important as mapping positive hits. The table below outlines the databases inspected where J&J MedTech has data limitations or where specific technical caveats apply.

Jurisdiction	Database Inspected	Finding / Status	Technical Caveat / Database Limitation
Switzerland	swissdamed (UDI Details)	LIMITATION	swissdamed's public device registration database is in phased rollout. While J&J holds active registrations, the query returns limited details compared to EUDAMED due to partial database transparency.
European Union	EUDAMED Certificates	LIMITATION (2 Certs)	Only 2 active certificates are visible under J&J-associated Actor IDs in EUDAMED. This reflects the delayed mandatory status of the EUDAMED Certificates module, which only became mandatory on May 28, 2026, meaning many notified bodies are still uploading legacy MDR certificates.
Oman	MOH Medical Devices	NO-HIT (Data Gap)	The database is currently restricted to local licensed sponsors; no public-facing search tool is available to extract manufacturer-specific listings.
Jordan	JFDA Medical Devices List	LIMITATION	Records are listed primarily at the local distributor level under brand names, making direct manufacturer queries incomplete.

Understanding Registry Data Limits: A Commercial Warning

A critical mistake made by market analysts, investors, and regulatory consultants is treating medical device registration records as equivalent to market share, product sales, or clinical usage. It is critical to recognize the inherent limits of registry datasets:

Registrations are Not Sales: An active registration simply indicates that a device has cleared regulatory hurdles and is legally allowed to be commercialized in that country. It does not mean the device is actively marketed, stocked, or utilized in local clinical settings. Conglomerates like J&J MedTech frequently maintain hundreds of legacy registrations for products that are commercially inactive or have been replaced by newer generations, simply because the administrative cost of maintaining the license is low compared to the cost of re-registering if market demand returns.
Record Counts do Not Equal Unique SKUs: The unit of measurement in registries is the "record" or "line count". A single registration record (or license) can cover hundreds of individual catalog numbers (SKUs), packaging sizes, or product configurations. Conversely, a single product line might be split across multiple registration records due to variations in manufacturing sites, component classifications, or regional packaging requirements.
Vigilance and Recalls reflect Report Counts, not Safety Incidence: In public safety databases, counts reflect administrative actions and reporting volume. Because J&J MedTech holds a vast market share in high-volume consumables (such as Ethicon sutures or Biosense Webster ablation catheters), the sheer volume of products in circulation naturally correlates to a higher absolute number of adverse events and recalls. This is a reflection of exposure, not a higher defect rate or inferior safety profile compared to low-volume competitors.
Distributor Lists are Channel Evidence, Not Approvals: In databases listing authorized importers or distributors, the presence of a J&J entity indicates a commercial channel setup rather than a technical product approval. A local distributor must be licensed to import, but they can only import products that have separately secured technical registration certificates.

Brand Portfolio & Acquisition Integration Analysis

J&J MedTech's global footprint is divided into distinct operating companies, many of which were integrated through major historical acquisitions. The registries reflect this structure, showing how these brands operate as distinct manufacturing entities.

graph TD
    JJ[Johnson & Johnson MedTech] --> DS[DePuy Synthes]
    JJ --> ET[Ethicon]
    JJ --> BW[Biosense Webster]
    JJ --> CV[Cerenovus]
    JJ --> AB[Abiomed]
    
    DS --> Ortho[Orthopedics & Spine]
    ET --> Surg[General & Robotic Surgery]
    BW --> EP[Electrophysiology]
    CV --> NV[Neurovascular]
    AB --> HR[Heart Recovery]

1. DePuy Synthes (Orthopedics & Spine)

DePuy Synthes represents J&J's orthopedics franchise, formed by the merger of DePuy (acquired by J&J in 1998) and Synthes (acquired in 2012 for $19.7 billion).

Registry Representation: DePuy Synthes is the single largest block of J&J MedTech registrations across every core registry, because its orthopedics catalogs span huge numbers of plates, screws, joint implants, spine systems, and instruments. In Health Canada's MDALL, the top DePuy/Synthes licensee entities include Synthes GmbH and DePuy Ireland UC, together accounting for thousands of active licenses. In Australia's ARTG, the dominant sponsor entry is Johnson & Johnson Medical Pty Ltd trading as DePuy Synthes. In the FDA Registration & Listing snapshot, the largest DePuy/Synthes establishment names include Synthes (USA) Products LLC, Synthes GmbH, DePuy Orthopaedics, Inc., and DePuy Spine, Inc.
Regulatory Complexity & Strategic Review: On October 14, 2025, Johnson & Johnson announced a planned divestiture/spinoff of its orthopedics (DePuy Synthes) business over the following 18–24 months. Regulatory affairs teams are watching registries closely: as legacy product codes are rationalized ahead of and after separation, the number of active DePuy listings is expected to decline gradually over several years (registrations are typically maintained until a product is officially discontinued and inventory clears). For more background on the separation, see our analysis of the J&J DePuy Synthes orthopedics strategic review.

2. Ethicon (Surgery)

Ethicon is J&J's foundational surgery franchise, spanning wound closure (sutures), biosurgery, endomechanical instruments, and energy devices (Harmonic, Enseal).

Registry Representation: Ethicon is J&J's second-largest registration block. In the FDA Registration & Listing snapshot, the largest Ethicon establishment is Ethicon, Inc.; in MDALL, Ethicon activity is split across Ethicon Endo-Surgery, LLC, Ethicon LLC, and Ethicon Inc.; in Australia's ARTG, Ethicon entities appear as the manufacturer of record under the local Johnson & Johnson Medical Pty Ltd sponsor. Ethicon registrations are split between "Ethicon Inc." (wound closure and biosurgery) and "Ethicon Endo-Surgery" (endomechanical and energy devices).
Robotic Integration: Ethicon's portfolio also includes registrations for the Monarch robotic endoscopy platform and the Ottava robotic surgical system, which are registered under specialized robotic surgical system product codes (such as FDA product code NAY).

3. Biosense Webster (Electrophysiology)

Biosense Webster is the global leader in cardiac arrhythmia diagnosis and treatment, specializing in electrophysiology (EP) mapping systems (CARTO) and ablation catheters.

Registry Representation: Biosense Webster appears as a focused but distinct registration block. In MDALL, the licensee entity is Biosense Webster, Inc.; in the FDA snapshot, the largest Biosense establishment is Biosense Webster, Inc.; in Australia's ARTG, Biosense Webster appears as a manufacturer of record under J&J's local sponsor entity.
Technology Transition: Regulators are tracking Biosense Webster's rapid rollout of Pulsed Field Ablation (PFA) catheters (such as the Varipulse platform), which are registered under new, distinct Class III/Class D classifications in major registries, replacing or supplementing legacy radiofrequency (RF) ablation catheters.

4. Cerenovus (Neurovascular)

Cerenovus is J&J MedTech's neurovascular business, focusing on hemorrhagic and ischemic stroke care (coils, stents, microcatheters, and clot retrievers).

Registry Representation: As a younger, more specialized business unit, Cerenovus holds a comparatively small, focused set of registrations — the Cerenovus, Inc. entity appears across the FDA, MDALL, and ARTG snapshots — reflecting a premium, narrow stroke-care portfolio rather than the broad catalog volumes of orthopedics or surgery.

5. Abiomed (Heart Recovery)

J&J acquired Abiomed on December 22, 2022, for an upfront transaction value of approximately $16.6 billion ($380 per share in cash plus a non-tradeable contingent value right of up to $35 per share). Abiomed operates as a standalone business within J&J MedTech.

Registry Representation: Abiomed's registrations remain distinctly identifiable under the Abiomed Inc. (USA) and Abiomed Europe GmbH / Abiomed Australia Pty Ltd legal entities across the FDA, MDALL, ARTG, and EUDAMED snapshots, centered on the Impella heart-recovery pump platform. Because Abiomed is a single-platform business, its registration count is small in absolute terms compared with DePuy Synthes or Ethicon.
Identity Integration: From January 2025, J&J MedTech officially aligned the Abiomed brand identity with the J&J MedTech corporate brand. However, in global device registries, the legal manufacturer remains "Abiomed Inc." (Covington, MA) or "Abiomed Europe GmbH" (Aachen, Germany), as changing the legal manufacturer on labels requires submitting variations to every regulator globally, a process that takes years.

Detailed Market Profiles & Registry Insights

To understand J&J MedTech's global footprint, we must look beyond numbers and inspect how J&J is represented in specific key databases.

1. United States: FDA CDRH Database

The United States represents J&J MedTech's home market and holds the largest concentration of records. The FDA Registration & Listing snapshot shows the scale of J&J's US manufacturing and listing footprint:

FDA Registration & Listing: Out of 417,036 total registered establishments and listing records in the snapshot, 4,449 records match the J&J brand-token set (DePuy, Ethicon, Biosense Webster, Cerenovus, Abiomed, Johnson & Johnson). The largest establishment names are dominated by DePuy/Synthes orthopedics entities (for example Synthes (USA) Products LLC, Synthes GmbH, DePuy Orthopaedics, Inc., DePuy Spine, Inc.) and Ethicon surgical entities (Ethicon, Inc.).
FDA 510(k) and PMA: The Registration & Listing snapshot counts establishment and product-listing lines rather than individual 510(k) clearances or PMA approvals, so we do not derive a comparable 510(k)/PMA total from it here. Directionally, J&J MedTech's 510(k) footprint is largest in surgery (Ethicon staplers, energy devices, sutures) and orthopedics (DePuy Synthes), while its PMA footprint is concentrated in Class III areas such as Biosense Webster electrophysiology/ablation, surgical robotics, and Abiomed Impella heart-recovery pumps.

2. Canada: Health Canada MDALL

Health Canada's Medical Devices Active License Listing (MDALL) represents one of the cleanest product-level registries in the world. It tracks active licenses for Class II, III, and IV medical devices:

Denominator: 152,560 active license records.
Combined J&J Matches: 2,343 active licenses (brand-token set; the true footprint is larger when standalone Synthes entities are included).
Analysis: The licensee breakdown makes the portfolio mix obvious: orthopedics dominates. The single largest J&J licensee entity in MDALL is Synthes GmbH, followed by DePuy Ireland UC — together accounting for the bulk of J&J's Canadian active licenses — with surgery (the Ethicon entities), electrophysiology (Biosense Webster, Inc.), neurovascular (Cerenovus, Inc.), and heart recovery (Abiomed Inc.) making up the remainder.
Subsidiary Breakdown: Other active licensee entities include Johnson & Johnson Medical Products (Mississauga, ON) and Johnson & Johnson Surgical Vision, Inc.

3. Australia: TGA ARTG

The Australian Register of Therapeutic Goods (ARTG) is the repository of all medical devices approved for supply in Australia.

Denominator: 99,405 records.
Combined J&J Matches: 2,223 sponsor or manufacturer listings (brand-token set).
Analysis: The sponsor side is consolidated under J&J's local subsidiary, Johnson & Johnson Medical Pty Ltd (North Ryde, NSW) — the largest single sponsor entry being Johnson & Johnson Medical Pty Ltd trading as DePuy Synthes, with additional entries under Johnson & Johnson Medical Pty Ltd and Johnson & Johnson Pacific Pty Ltd. On the manufacturing side, DePuy/Synthes is the dominant manufacturer of record, with Ethicon and Biosense Webster also appearing as manufacturers behind the local sponsor.
Sample Entry: A typical listing pattern is an Ethicon surgical suture entry, with Johnson & Johnson Medical Pty Ltd as sponsor and an Ethicon Inc. (USA) entity as manufacturer.

4. European Union: EUDAMED Registry

The European Union's EUDAMED database is under phased implementation. On May 28, 2026, EUDAMED reached a major milestone: mandatory use of the first four modules (Actor, UDI/Devices, Notified Bodies & Certificates, Market Surveillance) began.

Actor Registrations: J&J MedTech has registered 73 distinct Actor records (Single Registration Numbers, or SRNs) across Europe, representing its various legal manufacturing entities (e.g., DePuy Ireland UC, Ethicon Endo-Surgery, Biosense Webster Inc.) and authorized representatives.
Certificate Visibility: In the Notified Bodies & Certificates module, J&J currently shows only 2 active MDR certificates. This low count is a common industry-wide limitation: because the Certificates module is in its initial mandatory phase, notified bodies are prioritizing uploading certificates for new products over legacy MDD-to-MDR transition certificates. This demonstrates that EUDAMED certificate counts are not currently a reliable indicator of J&J's active European commercial portfolio.

Importer vs. Product Registration: Channel Footprint

In addition to product registries, mapping J&J MedTech's local importer and distributor networks provides insight into its regional commercial strategies.

Direct Subsidiary vs. Third-Party Distributor

The data shows a clear pattern: in major, high-volume markets, J&J MedTech operates via its own direct local subsidiaries, which act as the authorized importer or local representative of record. In smaller or more restricted markets, J&J relies on third-party local distributors:

Colombia (INVIMA): J&J operates via Johnson & Johnson de Colombia S.A. (based in Bogotá), which is listed as the registrant (Titular) for a substantial share of J&J's active INVIMA records. The company also holds a certified importer license (Certificado de Importador, CCAA).
South Korea (MFDS): J&J operates through 한국존슨앤드존슨메디칼(주) (Johnson & Johnson Medical Korea Ltd.), which is listed as a licensed importer in Seoul.
Canada (Health Canada MDEL): J&J operates through Johnson & Johnson Inc., holding an active Medical Device Establishment License (MDEL) in Mississauga, Ontario, which permits direct importation and distribution of Class I devices and general distribution.
Singapore (HSA): HSA registries list Johnson & Johnson Pte. Ltd. as a registrant for J&J's products, indicating a centralized direct regional hub.

This direct subsidiary model allows J&J to maintain tight control over its local supply chain, manage price structures, and coordinate directly with ministries of health. In contrast, in smaller markets or regions with complex distribution laws, registrations are often held by local third-party distributors, meaning J&J must coordinate its regulatory strategy through external intermediaries.

Sourcing and Supply Chain Integration

J&J MedTech's manufacturing network is highly globalized, which introduces unique regulatory and logistical dependencies. By analyzing the country of origin listed in global registries, we can map J&J's manufacturing hubs:

Orthopedics Implants (Cork, Ireland & Switzerland): The ANVISA and Health Canada databases show that a massive portion of DePuy Synthes' joint replacement implants are manufactured in Cork, Ireland, or in Synthes' legacy facilities in Switzerland (e.g., Zuchwil). These facilities are among the largest orthopedic manufacturing plants globally.
Surgical Sutures (San Angelo, USA & Juarez, Mexico): Registration details from the CDSCO and TGA reveal that Ethicon's surgical sutures (such as Vicryl and Prolene) are primarily manufactured in San Angelo, Texas, and assembled/packaged in Juarez, Mexico.
Electrophysiology Catheters (Juarez, Mexico & Irvine, USA): Biosense Webster's high-precision electrophysiology catheters are manufactured in Juarez, Mexico, and Irvine, California, highlighting the importance of the US-Mexico border corridor for advanced medtech assembly.
Heart Recovery Pumps (Aachen, Germany & Danvers, USA): Abiomed's Impella heart-recovery pumps are manufactured in Danvers, Massachusetts, and Aachen, Germany, representing specialized mechanical circulatory support clusters.

For supply chain managers, this distribution highlights the risk of tariff exposure. Products imported into the US from J&J's European facilities (such as Cork or Aachen) or from Mexican assembly sites face different tariff schedules compared to domestic US production.

Peer Comparison: J&J MedTech vs. Competitors

To contextualize J&J MedTech's footprint, we compare its registry metrics against other major medical technology conglomerates. J&J's diversified structure contrasts with the specialized focus of its peers.

J&J MedTech vs. Medtronic: Medtronic holds a larger absolute number of active registrations in high-risk cardiovascular and neurovascular segments, reflecting its position as the largest pure-play medical device company. However, J&J MedTech holds a larger registration footprint in surgical consumables and electrophysiology. For comparison, see the Medtronic FDA device footprint.
J&J MedTech vs. Stryker: Stryker is J&J's primary competitor in orthopedics (DePuy Synthes). Stryker competes across reconstructive joints, spine, trauma, and a broad medical-surgical equipment portfolio (beds, stretchers, surgical instruments) that drives large per-product registration volume. For a like-for-like registry comparison, consult the Stryker global medical device registrations dossier.
J&J MedTech vs. Zimmer Biomet: Zimmer Biomet is a pure-play orthopedics competitor. Its registrations are highly concentrated in reconstructive joint implants, where it competes head-to-head with DePuy Synthes, but it lacks J&J's surgery, electrophysiology, neurovascular, and heart-recovery franchises. See the Zimmer Biomet global medical device registrations dossier for details.
J&J MedTech vs. Abbott: Abbott's regulatory footprint is highly concentrated in active cardiovascular devices (such as pacemakers, ICDs, and structural-heart valves) and in vitro diagnostics (IVD), whereas J&J MedTech has no major IVD footprint but leads in surgical devices and electrophysiology. See the Abbott FDA device footprint for details.
J&J MedTech vs. BD: BD (Becton, Dickinson) has a massive footprint in high-volume, low-risk consumables (syringes, needles, pre-analytical collection tubes) and diagnostic reagents. Because BD's catalog skews toward commodity medical supplies, it typically holds very large registration volumes in registries such as Saudi Arabia's SFDA relative to its revenue — a different shape from J&J's higher-value surgical and orthopedic mix. See the BD global medical device registrations dossier for comparison.

FAQs

When did Johnson & Johnson acquire Abiomed and how does it appear in device registries?

Johnson & Johnson completed the acquisition of Abiomed on December 22, 2022, for approximately $16.6 billion. Although the brand was visually aligned under the J&J MedTech corporate identity in January 2025, Abiomed continues to appear in global device registries under its legacy legal manufacturer names, such as "Abiomed Inc." (USA) or "Abiomed Europe GmbH" (Germany).

Does J&J MedTech register under 'Johnson & Johnson' or under each brand?

J&J MedTech utilizes a hybrid approach. Registrations are typically held under the legacy legal manufacturer names listed on the product labels (e.g., "Ethicon Inc.", "DePuy Synthes Joint Reconstruction", "Biosense Webster Inc.") to avoid the massive cost and regulatory burden of updating labels globally. However, the local applicant or importer of record is typically the local J&J subsidiary (e.g., "Johnson & Johnson Medical Pty Ltd" in Australia or "Johnson & Johnson de Colombia S.A." in Colombia).

How many J&J MedTech actors are registered in EUDAMED and how many MDR certificates are visible?

J&J MedTech has registered 73 distinct Actor records (Single Registration Numbers, or SRNs) in EUDAMED. However, only 2 active MDR certificates are currently visible in the public database. This low certificate count is an industry-wide limitation resulting from the delayed mandatory uploading of legacy transition certificates by notified bodies following the May 28, 2026, EUDAMED mandate.

Is J&J MedTech's orthopedics (DePuy Synthes) footprint shrinking after the reported strategic review?

While J&J has undertaken a strategic review of its orthopedics business to improve margins, registries do not show a significant immediate drop in active listings. Regulatory licenses are typically maintained until a product is officially discontinued and all inventory is cleared, meaning any rationalization of the DePuy Synthes portfolio will appear in registries gradually over several years.

Internal Links and Context

For more information on large-scale medical technology mergers, see our guide on the Waters and BD Biosciences merger.
For information on general market access frameworks, see the USA medical device registration US agent pricing guide.
For general supply chain strategies, consult our comprehensive Medical device supply-chain risk management guide.
To see how J&J MedTech compares to other major orthopedic competitors, read the Stryker global medical device registrations dossier and the Zimmer Biomet global medical device registrations dossier.